5:17 PM
 | 
Dec 01, 2011
 |  BC Extra  |  Clinical News

Anthera reports blisibimod interim data in SLE

Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) said interim data from the Phase IIb PEARL-SC trial showed that subcutaneous blisibimod significantly reduced B cells in patients with systemic lupus erythematosus (SLE). Anthera...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >